Search clinical trials for: Epoetin Alfa plus Iron

Total 635 results

University of Louisville
James Graham Brown Cancer Center

Withdrawn

Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia (Procrit)

Anemia

United States
University of California, San Diego

Terminated

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

Anemia | Congenital Heart Disease | Cyanotic Congenital Heart Disease | Cyanosis

United States
University of Medicine and Dentistry of New Jersey
Ortho Biotech Clinical Affairs, L.L.C.

Terminated

Prevalence and Treatment of Anemia in Rehabilitation Patients

Anemia

United States
St. Bartholomew's Hospital

Unknown

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Western Galilee Hospital-Nahariya

Unknown

Prevention of Contrast Induced Nephropathy by Erythropoietin

Diabetes | Chronic Kidney Insufficiency

Israel
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease (CKD)

United States, Puerto Rico
University of Washington
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) (PENUT)

Extreme Prematurity

United States
Shahid Beheshti University of Medical Sciences
Pooyesh Darou

Completed

Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

Myocardial Ischemic Reperfusion Injury

Iran, Islamic Republic of
Jinling Hospital, China
Ministry of Health, China

Completed

Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia (CD-AT1)

Crohn's Disease

China
Huiqing Sun
Göteborg University; Zhengzhou University

Enrolling by invitation

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants (EPO)

Developmental Disabilities
Zhengzhou University
Göteborg University; Zhengzhou Children's Hospital, China

Completed

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

Premature Infants

China
Hospital de Clinicas de Porto Alegre
Oswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RS

Completed

Efficacy Study of Two Formulations of Erythropoietin

Comparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
Megalabs
Azidus Laboratories

Not yet recruiting

Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients (ENCASE)

Anemia of Chronic Kidney Disease

Uruguay
M.D. Anderson Cancer Center

Completed

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Leukemia

United States
Sheba Medical Center

Unknown

Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

Retinopathy of Prematurity

Israel
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (Pyrenees)

Anemia | End Stage Renal Disease (ESRD)

Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Russian Federation, Serbia, Spain, United Kingdom, Belgium, France, Georgia, Italy, Portugal, Romania, Slovakia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech, Inc.

Completed

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Anemia | Venous Thrombosis
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Kidney Diseases | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Cancer | Anemia | Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)

Anemia | Blood Transfusion | Orthopedic Procedures
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Anemia

United States, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Critical Illness | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Cancer | Anemia

United States
Janssen-Ortho Inc., Canada
Ontario Clinical Oncology Group (OCOG)

Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Carcinoma | Prostate
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Lymphoma | Leukemia | Breast Cancer | Chronic Myeloproliferative Disorders | Anemia | Small Intestine Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Drug/Agent Toxicity by Tissue/Organ

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Terminated

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Myelodysplastic Syndromes | Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Anemia

United States
Fundación Pública Andaluza para la gestión de la...

Completed

Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period (PAHFRAC)

Hip Fractures

Spain
Janssen-Cilag B.V.

Completed

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

Neoplasms | Anemia

Netherlands
Janssen-Cilag B.V.

Completed

Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)

Neoplasms | Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Anemia | HIV
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Stomach Neoplasms | Rectal Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer

Anemia
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Anemia | Chronic Kidney Disease
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety of Epoetin Alfa and Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients After Major Orthopedic Surgery.

Anemia | Blood Transfusion | Orthopedic Procedures
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Blood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Cardiovascular Surgical Procedure | Blood Transfusion, Autologous
Janssen-Ortho Inc., Canada

Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Anemia
Janssen Cilag S.A.S.

Terminated

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Anemia | Renal Failure, Chronic Renal Failure
Janssen Pharmaceutica N.V., Belgium

Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Chronic Renal Failure
Amgen

Completed

Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.

Anemia
Jonsson Comprehensive Cancer Center
Amgen

Completed

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant Condition

United States
Amgen

Completed

Efficacy of Epoetin Alfa Deep Tank in Treatment of Anemia in Patients With Chronic Kidney Disease Receiving Hemodialysis

Nephrology
GlaxoSmithKline
Quintiles, Inc.; ERT: Clinical Trial Technology Solutions; Q2 Solutions; HemoCue

Completed

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Anaemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Products, L.P.

Terminated

PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Anemia | Surgery, Arthroscopy

3

Subscribe